166 related articles for article (PubMed ID: 36114954)
1. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Lavacchi D; Personeni N; Ratti F; Pedica F; Della Corte A; Persano M; De Cobelli F; Aldrighetti L; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2022 Sep; 17(5):591-596. PubMed ID: 36114954
[TBL] [Abstract][Full Text] [Related]
2. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Soldà C; Cito P; Nasti G; Lavacchi D; Zanuso V; Rizzato MD; Zaniboni A; Ottaiano A; Persano M; Cornara N; Scartozzi M; Cascinu S; Casadei-Gardini A
Ther Adv Med Oncol; 2023; 15():17588359231171574. PubMed ID: 37457302
[TBL] [Abstract][Full Text] [Related]
3. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
[TBL] [Abstract][Full Text] [Related]
5. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
[TBL] [Abstract][Full Text] [Related]
6. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
8. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
9. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990
[TBL] [Abstract][Full Text] [Related]
10. Ivosidenib Boosts OS in Cholangiocarcinoma.
Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569
[TBL] [Abstract][Full Text] [Related]
11. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
Fan B; Abou-Alfa GK; Zhu AX; Pandya SS; Jia H; Yin F; Gliser C; Hua Z; Hossain M; Yang H
Cancer Chemother Pharmacol; 2024 May; 93(5):471-479. PubMed ID: 38278871
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan.
Chen KA; Huang WM; Chen EY; Ho PK; Chueh CH; Wen YW; Chen MH; Chiang NJ; Tsai YW
BMC Cancer; 2024 May; 24(1):622. PubMed ID: 38778261
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
[TBL] [Abstract][Full Text] [Related]
15. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
16. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
Rabehi T; Quesada S
Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
[No Abstract] [Full Text] [Related]
17. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
18. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
Uson Junior PLS; Borad MJ
Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of ivosidenib for the treatment of
Tella SH; Mahipal A
Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
